ATN expects 2026 adjusted EBITDA at high end or modestly above $183M-$193M range as tower sale proceeds continue

Nexstar targets leverage closer to 3x while expecting CW’s first profitable quarter in Q4 2026

Haemonetics outlines FY 2027 organic growth of 6%-9% while scaling CSL Persona PLUS rollout through calendar 2027

Mgic signals operating expenses slightly below $190M-$200M range while extending quota share reinsurance to 2029

Global Payments signals $650M Worldpay run-rate expense synergies by end of 2028 while reiterating $2B+ 2026 shareholder returns